Aptose Biosciences Inc. Company Review & Valuation
About Aptose Biosciences Inc.
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada.
The company's clinical programs is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
It has an agreement with CrystalGenomics, Inc.
to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in late preclinical development stage for the treatment of patients with relapsed/refractory acute myeloid leukemia and having B-cell malignancies.
The company also has an agreement with Ohm Oncology for development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules.
The company was formerly known as Lorus Therapeutics Inc.
and changed its name to Aptose Biosciences Inc.
in August 2014.
Aptose Biosciences Inc.
was founded in 1986 and is headquartered in Mississauga, Canada.